Business
Consortium incl. ValiRx Awarded Eurostars Grant
Consortium incl. ValiRx Awarded Eurostars Grant.
About this update from Valirx Plc
[{"type":"text","content":"\n \nRNS Number : 7331L ValiRx PLC 15 August 2013 \n\n \n \n \n \n15 August 2013\nValiRx Plc\n(\"ValiRx\" or the \"Company\")\n \nConsortium including ValiRx Awarded New Eurostars Grant\n \nValiRx Plc (AIM: VAL), a life science company with a focus on cancer therapeutics for personalised medicine, is pleased to announce that the consortium, which comprises ValiRx and Pharmatest Services Limited has been awarded a prestigious new Eurostars grant.\n \nThe grant to the consortium is for up to €1.6 million and the funds will be used to progress the pre-clinical studies of VAL101, the Company's lead candidate deriving from the GeneICE platform and to build the associated cancer models. Additionally, some funding is for further GeneICE compounds directed at known Cancer targets. \n \nThis award follows the previous Eurostars grant of €1.4 million, the programme in respect of which was completed earlier this year and was accepted by both the Technology Strategy Board (TSB) and the Eurostars Team, as reported on 31 July 2013. \n \nDr Satu Vainikka, Chief Executive, commented:\n\"I am delighted to see and grateful for continued support from the Eurostars programme. Their grant will substantially help progress our work on VAL101 and GeneICE, which will in turn we believe, build value\".\n \n- ENDS -\n \nFor more information, please contact:\n \n\n\n\n\nValiRx plc\n\n\nTel: +44 (0) 20 3008 4416\n\n\n\n\nDr Satu Vainikka\n\n\nwww.ValiRx.com\n\n\n\n\n\n\n\n\n\n\n\n\nCairn Financial Advisers LLP (Nominated Adviser)\n\n\nTel:+44 (0) 20 7148 7900\n\n\n\n\nLiam Murray / Avi Robinson\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nHybridan LLP (Broker)\n\n\nTel: +44 (0) 20 7947 4350 / 4361\n\n\n\n\nClaire Louise Noyce / William Lynne\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPeckwater PR\n\n\nTel: +44 (0)7879 458 364\n\n\n\n\nTarquin Edwards\n\n\[email protected]\n\n\n\n\n\n\n\n\n\n\n\n\n \n \nNotes for Editors \nValiRx Plc \nValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases. \n \nThe Company listed on AIM in ...